24 results
8-K
EX-10.1
SQZB
SQZ Biotechnologies Co
7 Jul 23
Departure of Directors or Certain Officers
4:30pm
signature.
On behalf of the entire leadership team, thank you for your continued hard work and dedication toward SQZ’s success.
Sincerely,
/s/ David First
David First
Acknowledged and agreed (return by July 12, 2023):
EMPLOYEE
PRE 14A
SQZB
SQZ Biotechnologies Co
10 Apr 23
Preliminary proxy
4:31pm
held clinical development leadership roles at Bristol-Myers Squibb Corporation and Millennium Pharmaceuticals. Before joining the biopharmaceutical … . Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division
8-K
EX-99.1
SQZB
SQZ Biotechnologies Co
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
and I would like to sincerely thank Armon for his vision and leadership at SQZ over the past decade and his willingness to remain available to advise … strategic prioritization, the timing and outcome of the company’s clinical trials, cash use and availability, leadership and upcoming events and presentations
8-K
SQZB
SQZ Biotechnologies Co
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
of the Plan, the timing and outcome of the Company’s clinical trials, the Company’s cash use and availability, and leadership. These forward-looking
8-K
6b7adw75jykqjz4vgco
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
EX-99.1
wwf6b29t
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
EX-99.1
1au0z92ak7
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
EX-99.1
wv8rmr7 5a
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
DEF 14A
t1991y73hg
26 Apr 21
Definitive proxy
5:00pm
10-K
iyjp2jspnt4niaz
18 Mar 21
Annual report
6:31am
424B4
ciukxxk
12 Feb 21
Prospectus supplement with pricing info
5:10pm
DRS
eeai ckejo5abzs12sy
1 Feb 21
Draft registration statement
12:00am
10-Q
ipbkpkeb9w
10 Dec 20
Quarterly report
4:46pm
424B4
9eh2vl41v2 93d
30 Oct 20
Prospectus supplement with pricing info
4:54pm